FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2242314523> ?p ?o ?g. }

• W2242314523 abstract "8121 Background: Attempts to combine total body irradiation (TBI) with high-dose melphalan (Mel) resulted in substantial organ toxicities and precluded optimal dosing of Mel. Helical tomotherapy may allow delivery of total marrow irradiation (TMI), while avoiding collateral toxicities. Methods: We designed a phase I/II study for patients (pts) with responding or stable stage I-III MM. Following PBPC mobilization, pts receive THDT first with Mel 200 mg/m 2 and PBPC, and, ≥ 6 weeks later, escalating doses of TMI (starting dose: 200 cGy daily × 5 [1,000 cGy], up to 200 cGy twice daily × 5 days [2,000 cGy]) and PBPC. Maintenance consists of dexamethasone 40 mg/day × 4 days every 28 days and thalidomide 50–200 mg/day. Results: The median number of prior chemotherapy regimens is 2 (1- 4). The median duration from diagnosis to the HDT is 8 mos (4–13). Median age of pts is 53 (35–66). Sixteen pts with stages II (6) and III (10) MM have received Mel; 15 of 16 pts (8F/8M) have received treatment at dose levels 1–5 of TMI (1,000 cGy through 1,800 cGy); 1 pt is about to start TMI at 1,800 cGy. The median time between the first and second THCT cycles is 74 days (47–125). Hematopoietic toxicities were independent of TMI dose levels: granulocyte recovery to >1,000/microliter following Mel required 12 days (11–38) versus a median of 10 days after TMI (range; 9–12). Platelet (excluding 6 pts not needing plt transfusion) independence was seen by day 10 (8–13) versus 8 (6–11) following TMI. In the first 15 pts the estimated median radiation dose to normal organs was 15–60% of the targeted bone marrow dose. Reversible grade 3 non-hematologic toxicities by TMI dose levels included fatigue and febrile neutropenia (FN) (level 1: 1 pt each), FN (level 2: 1 pt); none (level 3); fatigue (level 4: 2 pts); anorexia and stomatitis (level 5: 1pt; anorexia: 1 pt). The median follow-up is 8 mos (3–21); 1 pt progressed at 8 mos. Final data on toxicities including patients already in screening for treatment at TMI 2,000 cGy, tolerability of maintenance, and response rate will be presented. Conclusion: TMI is feasible and could potentially be useful as part of THDT for patients with MM. No significant financial relationships to disclose." @default.
• W2242314523 created "2016-06-24" @default.
• W2242314523 creator A5005253200 @default.
• W2242314523 creator A5023917993 @default.
• W2242314523 creator A5025887498 @default.
• W2242314523 creator A5035985145 @default.
• W2242314523 creator A5038274786 @default.
• W2242314523 creator A5039374832 @default.
• W2242314523 creator A5046784402 @default.
• W2242314523 creator A5057798024 @default.
• W2242314523 creator A5065938090 @default.
• W2242314523 creator A5082853715 @default.
• W2242314523 date "2007-06-20" @default.
• W2242314523 modified "2023-09-26" @default.
• W2242314523 title "Phase I trial of escalating doses of total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan and PBPC as part of tandem high-dose therapy (THDT) for patients with multiple myeloma (MM)" @default.
• W2242314523 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.8121" @default.
• W2242314523 hasPublicationYear "2007" @default.
• W2242314523 type Work @default.
• W2242314523 sameAs 2242314523 @default.
• W2242314523 citedByCount "0" @default.
• W2242314523 crossrefType "journal-article" @default.
• W2242314523 hasAuthorship W2242314523A5005253200 @default.
• W2242314523 hasAuthorship W2242314523A5023917993 @default.
• W2242314523 hasAuthorship W2242314523A5025887498 @default.
• W2242314523 hasAuthorship W2242314523A5035985145 @default.
• W2242314523 hasAuthorship W2242314523A5038274786 @default.
• W2242314523 hasAuthorship W2242314523A5039374832 @default.
• W2242314523 hasAuthorship W2242314523A5046784402 @default.
• W2242314523 hasAuthorship W2242314523A5057798024 @default.
• W2242314523 hasAuthorship W2242314523A5065938090 @default.
• W2242314523 hasAuthorship W2242314523A5082853715 @default.
• W2242314523 hasConcept C126322002 @default.
• W2242314523 hasConcept C126894567 @default.
• W2242314523 hasConcept C141071460 @default.
• W2242314523 hasConcept C2776694085 @default.
• W2242314523 hasConcept C2776713427 @default.
• W2242314523 hasConcept C2776755627 @default.
• W2242314523 hasConcept C2777288759 @default.
• W2242314523 hasConcept C2778684742 @default.
• W2242314523 hasConcept C2778880498 @default.
• W2242314523 hasConcept C2780007613 @default.
• W2242314523 hasConcept C2989005 @default.
• W2242314523 hasConcept C509974204 @default.
• W2242314523 hasConcept C71924100 @default.
• W2242314523 hasConceptScore W2242314523C126322002 @default.
• W2242314523 hasConceptScore W2242314523C126894567 @default.
• W2242314523 hasConceptScore W2242314523C141071460 @default.
• W2242314523 hasConceptScore W2242314523C2776694085 @default.
• W2242314523 hasConceptScore W2242314523C2776713427 @default.
• W2242314523 hasConceptScore W2242314523C2776755627 @default.
• W2242314523 hasConceptScore W2242314523C2777288759 @default.
• W2242314523 hasConceptScore W2242314523C2778684742 @default.
• W2242314523 hasConceptScore W2242314523C2778880498 @default.
• W2242314523 hasConceptScore W2242314523C2780007613 @default.
• W2242314523 hasConceptScore W2242314523C2989005 @default.
• W2242314523 hasConceptScore W2242314523C509974204 @default.
• W2242314523 hasConceptScore W2242314523C71924100 @default.
• W2242314523 hasLocation W22423145231 @default.
• W2242314523 hasOpenAccess W2242314523 @default.
• W2242314523 hasPrimaryLocation W22423145231 @default.
• W2242314523 hasRelatedWork W2022633161 @default.
• W2242314523 hasRelatedWork W2063921899 @default.
• W2242314523 hasRelatedWork W2596203944 @default.
• W2242314523 hasRelatedWork W2615054509 @default.
• W2242314523 hasRelatedWork W2907783793 @default.
• W2242314523 hasRelatedWork W3030099324 @default.
• W2242314523 hasRelatedWork W3032524280 @default.
• W2242314523 hasRelatedWork W3210375626 @default.
• W2242314523 hasRelatedWork W4220728847 @default.
• W2242314523 hasRelatedWork W4220890061 @default.
• W2242314523 isParatext "false" @default.
• W2242314523 isRetracted "false" @default.
• W2242314523 magId "2242314523" @default.
• W2242314523 workType "article" @default.